AstraZeneca experienced positive trading momentum following the announcement of a strategic artificial intelligence drug discovery partnership with California-based insitro valued at up to $1.5 billion. The deal focuses on discovering and developing novel treatments for metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies. Investors reacted favorably to the risk-mitigated deal structure, which requires a modest initial cash outlay while securing exclusive global rights to potential commercial assets. This collaboration underscores management’s commitment to expanding its pre-clinical pipeline in high-need cardiovascular and metabolic indications without overextending near-term capital deployment.

The positive…